Bayer (BAYRY)
(Delayed Data from OTC)
$7.28 USD
-0.14 (-1.83%)
Updated Jul 23, 2024 01:54 PM ET
4-Sell of 5 4
B Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
BAYRY 7.28 -0.14(-1.83%)
Will BAYRY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BAYRY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BAYRY
Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
BAYRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Bayer's (BAYRY) AskBio Advances Parkinson Disease Study
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Other News for BAYRY
J.P. Morgan Sticks to Its Hold Rating for Bayer (0P6S)
ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value
Bayer (0P6S) Gets a Hold from J.P. Morgan
Bayer (0P6S) Receives a Hold from Goldman Sachs
Bayer says darolutamide boosts survival in prostate cancer trial